

Global rights to risk managed biosimilars at scale

- NeuClone and the Serum Institute of India (SIIPL) are developing 10 biosimilar Wave II and Wave III antibody products for global commercialization
- High quality, affordable biosimilars are made possible through NeuClone's technology and the company's Right from the Start® approach to development, as well as SIIPL's expertise in large scale manufacture
- NeuClone is responsible for upstream development of all biosimilars while SIIPL is responsible for process development and FDA/EMA compliant manufacture of finished product
- NeuClone and SIIPL are jointly performing early clinical development through to completion of Phase I trials
- Four biosimilar products have been transferred by NeuClone to SIIPL with an additional six to follow
- STELARA and HERCEPTIN biosimilars to enter Phase I in 2018
- HUMIRA, SYNAGIS and PROLIA biosimilars enter clinical studies in 2019
- NeuClone and SIIPL are pursuing a broad portfolio across cancer, autoimmune disease and infectious disease
- We provide Phase III-ready biosimilars via Serum Institute and seek commercialisation partners to prosecute the Phase III studies, however co-investment in Phase III is also possible

Biosimilars, Right from the Start®

NeuClone is positioned early in biosimilar development and has implemented a Right from the Start® approach to developing biosimilar candidates which consists of three core attributes:



Right Sequence - Early focus on primary structure (amino acid sequence) identification of originator through proprietary processes involving Peptide Mass Fingerprinting (PMF), intact mass and X-ray crystallography.

Right Approach - *Biosimilarity by Design™* approach based on QbD principles to test and confirm biosimilarity from the earliest stages and throughout development to ensure biosimilarity is achieved downstream.

Right Price - NeuClone's NeuMAX® technology, incorporated at the start of development, allows for the low-cost manufacture of biosimilars and contributes to affordability and pricing flexibility.

Why NeuClone Technology

- NeuClone's NeuMAX® platform allows for the low cost manufacture of biologics and includes a proprietary vector system, medium and robust parental cell line. The parental cell line, NeuCHO®, delivers increased viable cell density and extends culture life, allowing for increased yields on harvest compared to standard CHO cells.
- Cell expression system - US patent granted



Quality, Capacity, Cost

- NeuClone ensures biosimilar quality downstream by focussing on the earliest and most risk intensive stages of development – ensuring biosimilars are Right from the Start®
- SIIPL complements this with process experience and large cGMP manufacturing capacity for global supply
- The NeuClone/SIIPL partnership is aimed at becoming a cost leader in the global supply of FDA/EMA quality biosimilars
- Lowest drug supply price globally allows partners to enter the market, at any stage, grow these markets and maintain ROI despite competitors
- We encourage our licensing partners to propose a supply price and allow us to demonstrate our market-leading supply price commitment
- In addition, NeuClone has five new biosimilar products initiated as at IQ 2018 and also available for partnering

NeuClone/SIIPL Responsibilities

NeuClone

- Upstream development and characterisation
- Initial process development and biosimilarity screening

Joint

- Pre-clinical analytics (top 5 CRO)
- PK/PD clinical program (top 5 CRO)

SIIPL

- Process development and scale up
- cGMP manufacture, fill and finish
- Marketing and distribution to ROW

Commercial opportunity created by NeuClone and SIIPL

The major opportunity is the Developed World Markets

- The current originator market is constrained in size by high price and limited product availability
- NeuClone and SIIPL can expand the current originator market by producing affordable high quality products for new patients

Emerging biosimilars market also an opportunity

- Emerging markets are constrained by price and availability of biologics and demand is estimated to be four times the current originator market in patient numbers

Unique differentiation of NeuClone through partnering with SIPL

- 10 biosimilar mAb products across various therapeutic classes that are available for global partnering
- Simplified path to commercialisation as NeuClone and SIPL take on all CAPEX and operating requirements of product manufacture. Partners can retain internal focus and investment on Phase III and later commercialisation steps without manufacturing burden and associated direct investments
- Industry leading scientific team in upstream biologics development and analytics
- Quality indistinguishable from originator based on Right from the Start® approach
- As SIPL has achieved in its historical business as the world's largest supplier of vaccines (by number of doses supplied), SIPL is committed to bringing **game-changing, disruptive supply pricing** to biosimilar mAbs, and hence the global competitive landscape
- Serum Institute will supply FDA/EMA cGMP quality product BELOW the supply pricing level possible by any current or projected future biosimilars supplier. SIPL is committed to drive unique affordability
- Partnering post first human dose in Phase I greatly de-risks development and increases probability of success

Who is SIPL?

Worldwide leader in biologicals

- Largest volume and doses manufacturer of vaccines globally (used in 170 countries)
- 65% of the world's children receive at least one SIPL vaccine
- Produces over 50 vaccine products each with different production processes. Experienced in all steps of scale-up, manufacture and formulation.
- SIPL aims to replicate its vaccine success with biosimilars through high quality, affordable, large scale production, for global supply

Proven biosimilars capacity

- Successful scale up to commercial volumes of erythropoetin and a fully human rabies monoclonal antibody
- Scale up of NeuClone's HERCEPTIN biosimilar

Conforming to the highest standards

- Compliance with US FDA and EMA requirements
- Facilities in Holland (EU certified), the Czech Republic and India
- Large capacity with purpose built facility exclusively for NeuClone biosimilar mAbs

NC-SIPL Pipeline

Originator	Early Preclinical	Late Preclinical	Process Scale-up	Phase I	Phase III
Herceptin	█	█	█	2018	█
Stelara	█	█	█	2018	█
Humira	█	█	█	2019	█
Synagis	█	█	█	2019	█
Prolia/Xgeva	█	█	█	2019	█

[As at January 2018; 6 more products initiated]

Seeking product licensing and clinical development collaborations

We seek several commercial partner attributes

- A channel to global markets to maximize our long term commercial return
- Leadership in design and execution of confirmatory Phase III clinical studies for registration in US and EU
- Capacity and commitment to co-finance late clinical development
- Early engagement to allow coordinated design of clinical program
- A manufacturing supply agreement with SIPL

John Oksinski
 Head of Global Business Development
 Mobile: +61 429 133 767
 Email: j.oksinski@neuclone.com